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Abstract
Objectives: Adjuvant gemcitabine with or without chemoradiation is a standard therapeutic option for
patients with resected pancreatic cancer. The feasibility and toxicity of gemcitabine with docetaxel
before and after 5-fluorouracil (5FU)-based chemoradiation in the adjuvant pancreatic and biliary
cancer setting were investigated.
Methods: After a curative-intent resection, eligible patients with pancreaticobiliary cancers were trea-
ted with two cycles of gemcitabine and docetaxel followed by 5FU-based chemoradiation. Four weeks
after completing chemoradiation, two cycles of gemcitabine and docetaxel were administered. The
primary endpoint was the incidence of severe toxicities. Secondary endpoints included disease-free
survival (DFS) and overall survival (OS).
Results: Fifty patients with pancreaticobiliary cancers were enrolled. Twenty-nine patients had pan-
creatic cancer whereas 21 patients had biliary tract or ampullary cancers. There was one death as a
result of pneumonia, and 15% of patients experienced grade 3 or greater non-haematological toxici-
ties. The median DFS and OS for patients with pancreatic cancer were 9.6 and 17 months, respec-
tively, and for those with resected biliary tract cancer were 12 and 23 months, respectively.
Conclusions: This combination of gemcitabine and docetaxel with chemoradiation is feasible and tol-
erable in the adjuvant setting. Future studies utilizing a different gemcitabine/taxane combination and
schedule may be appropriate in the adjuvant treatment of both pancreatic cancer and biliary tumours.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer death in
the United States.1 Surgical resection is curative, however, only
20% of patients present with resectable pancreatic cancer. The
5-year overall survival (OS) rate for patients with resected pan-
creatic cancer is low at 20–25%.2 Cancers of the biliary tract,
ampulla of Vater and gallbladder are uncommon cancers.
Similar to pancreatic cancer, most patients with cholangiocar-
cinoma or gallbladder carcinoma present with locally advanced
or metastatic disease. The prognosis is poor with these
tumours with a 5-year OS of < 5% reported in several retro-
spective studies.3–8
Adjuvant therapy for resected pancreatic cancer has been
established based on multiple positive randomized trials.9–13 A
multivariate analysis of the ESPAC-3 study demonstrated a sig-
nificant survival benefit for adjuvant chemotherapy for patients
with periampullary cancers.14 Only one randomized study
demonstrated the benefit of adjuvant chemotherapy for gall-
bladder cancer.15 A meta-analysis supported the use of adju-
vant therapy for resected biliary tract cancers especially for
patients with lymph node involvement and R1 resection.16Clinical trial information: NCT00660699
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Adjuvant gemcitabine improved the 5-year OS compared
with observation [20.7% versus 10.4%, hazard ratio (HR) 0.76,
P = 0.01] for patients with resected pancreatic cancer.9 Com-
pared with 5-fluorouracil (5FU), adjuvant gemcitabine con-
ferred comparable median survival times (23 versus
23.6 months, P = 0.39) but was associated with a better safety
profile.10 Gemcitabine administered pre- and post-chemoradia-
tion also resulted in a 5-year OS of 22% (versus 18% with
5FU, P = 0.08).12
Building on this gemcitabine-based chemoradiation plat-
form, the addition of a taxane, docetaxel, to gemcitabine in the
adjuvant setting for pancreaticobiliary cancers prior to, and
after, 5FU-based chemoradiation for patients with resected
pancreatic and biliary tract cancers was investigated. A phase II
study by the European Organisation for Research and Treat-
ment of Cancer (EORTC) showed better survival and safety
with the combination of gemcitabine plus docetaxel over cis-
platin plus docetaxel in mestastatic pancreatic cancer.17 The
GTX regimen with the docetaxel, gemcitabine, capecitabine
regimen showed a median survival of 11.3 months in meta-
static disease and 25 months with locally advanced disease.18
The aim of the present study was to establish the feasibility
and safety of gemcitabine plus docetaxel with 5FU chemoradia-
tion for patients with resected pancreaticobiliary cancers.
Patients and methods
Eligibility
Patients 18 years or older with biopsy-proven, curatively
resected cholangiocarcinoma, gallbladder, pancreatic or ampul-
lary adenocarcinoma were eligible. Other eligibility criteria
included the following: Eastern Cooperative Oncology Group
(ECOG) Performance Status (PS) of 0–2, no prior chemother-
apy or radiation therapy and at least 3 weeks had elapsed since
any surgery requiring general anaesthesia. Required laboratory
values included absolute neutrophil count (ANC) ≥ 1500/mm3,
platelet count ≥ 150 000/mm3, haemoglobin ≥ 9 g/dl, serum
creatinine ≤ 2 mg/dl, bilirubin ≤ 3.0 mg/dl and serum trans-
aminases ≤ five-fold the institutional upper limits. Exclusion
criteria included prior malignancies except basal or squamous
skin cancers, cervical carcinoma in situ and co-existing severe
medical illnesses, such as unstable angina, uncontrolled diabe-
tes mellitus, uncontrolled arrhythmia or an uncontrolled infec-
tion. The study was approved by our Institutional Review
Board (IRB) and informed consent was obtained from all
participants prior to enrolment.
Study design and treatment plan
This was an open-label, single-arm phase II study. The primary
aim was to evaluate the feasibility and toxicities associated with
this regimen. Stopping rules according to the sequential proba-
bility rate method was used to ensure accrual was stopped
should excessive severe toxicities occur (defined as > 30%
grade 3–5 non-haematologic adverse events). Institutional Data
and Safety Monitoring (DSM) was performed. Chemotherapy
began within 8–12 weeks after surgery. Gemcitabine was given
at a dose of 1000 mg/m2 as a 30-min intravenous (i.v.) infu-
sion on days 1 and 8 with docetaxel at 35 mg/m2 i.v. on days
1 and 8 of a 21-day cycle for two cycles prior to radiation
therapy. 5FU was given at 225 mg/m2 per day as a continuous
infusion throughout radiation starting 3 weeks after the second
cycle of gemcitabine. Radiation was given with computed
tomography (CT) based three-dimensional (3D) treatment
planning. Patients received a daily dose of 1.8 Gy 5 days per
week to a planning target volume 1 (ptv1) which included
celiac trunk and nodes, porta hepatis after the portal vein from
the hilum of the liver to the confluence with the superior mes-
enteric vein, paraaortic and paracaval nodes at the level of the
tumour bed and pancreatico-duodenal nodes. After 45 Gy,
portals were reduced to encompass planning target volume 2
(ptv2) that included the pre-operative tumour bed and gross
tumour volume. The boost dose to ptv2 would be determined
by the tolerance of the extraduodenal small bowel. Three to
4 weeks after completing chemoradiation, two more cycles of
gemcitabine and docetaxel were given.
Assessment of toxicity and efficacy
At study entry, a full history and a physical examination were
obtained, including vital signs, height and weight, ECOG per-
formance status and toxicity assessment. Prior to enrolment, a
complete blood count, comprehensive metabolic profile-human
chorionic gonadotropin in females, lactic dehydrogenase as
well as tumour markers including carbohydrate antigen 19-9
(CA19-9) and carcinoembryonic antigen (CEA)and a baseline
CT scan of the chest, abdomen and pelvis were obtained. At
the start of each cycle, as well as at the end of the treatment, a
history and physical examination were performed, as well as
laboratory studies above.
Responses were classified according to the Response Evalua-
tion Criteria in Solid Tumors (RECIST 1.0). Toxicity was
graded according to National Cancer Institute Common Toxic-
ity Criteria (NCI-CTC) version 2.0. For patients who devel-
oped treatment-related toxicities, the doses of gemcitabine,
docetaxel and 5FU were adjusted according to protocol-defined
parameters. Treatments were delayed if the ANC was
< 1500 cells/ml and platelet counts were <75 000 cells/ml, or
for any Grade III non-haematological toxicities or any hyper-
sensitivity reaction. Upon recovery, gemcitabine, docetaxel or
5FU doses were reduced by 25% when therapy was resumed.
For patients who developed Grade III or IV toxicity, both radi-
ation and chemotherapy were held until the toxicity resolved
to Grade 2 or less. Grade II or less toxicities were treated
symptomatically with supportive care. After the completion of
study treatments, patients were followed with clinic visits and
tumour markers every 3 months for survival and scans were
obtained every 6 months for 2 years and then annually for an
additional 3 years.
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Study endpoints and statistical analysis
The primary endpoint of this study was the incidence of severe
toxicities. Secondary endpoints included tumour response, dis-
ease-free survival (DFS) and OS. OS was defined as the time
from the initiation of treatment to death from any cause or
last follow-up, whereas DFS was defined as the time from the
initiation of treatment to relapse or death, whichever occurred
first. The data analysis was descriptive in nature. Patient demo-
graphic and clinical characteristics were summarized using
mean (standard deviation) or counts (frequency) as appropri-
ate. The median OS and DFS, 1- and 2-year OS and DFS, as
well as their 95% confidence intervals, were estimated using
the Kaplan–Meier product-limit method. All analyses were per-
formed using statistical packages SAS 9.3 (SAS Institutes, Cary,
NC, USA).
Results
Patient characteristics
From February 2003 to June 2010, 50 patients were enrolled:
29 patients (58%) had pancreatic cancer, nine patients (18%)
had ampullary cancer and 12 patients (24%) had biliary tract
cancers. Out of all the patients, 29 of those were male and 21
were female. The majority of the patients were Caucasian (44)
and only six patients were African American. Twenty-four
patients had an ECOG score 0 and 26 patients had ECOG 1.
The mean follow-up was 24 months (range 3.2–97). The distri-
bution of various baseline patient characteristics is shown in
Table 1. The median age at the time of study entry was
59 years (range, 41–76).
Treatment
Of the 50 patients enrolled, two withdrew consent prior to any
study therapy as a result of insurance and transportation
issues. Out of 48 patients who received at least one cycle of
chemotherapy, 30 patients (62.5%) completed all aspects (pre-
and post RT chemotherapy and 5FU-based CRT) of the study
treatment. Thirty-seven patients (77%) received pre-RT che-
motherapy with radiation. Eight patients (16%) did not com-
plete study treatment owing to early disease progression during
therapy. Ten patients (21%) did not complete all planned
study treatment owing to adverse events or physician decision.
Out of the 30 patients who completed all study treatments,
14 patients had pancreatic cancer, and 16 had biliary and
ampullary cancers. Seventeen patients (57%) required a 25–
50% dose reduction of gemcitabine and taxotere. Only eight
patients (26%) required a 25% reduction of 5FU during
chemoradiation. All patients tolerated full-dose radiation.
Adverse events
All 48 patients who received any study treatment were evalu-
able for toxicity assessments.
There was one death during the study as a result of clostrid-
ium difficile complicated with ventilator-acquired pneumonia.
Seven patients (14.5%) discontinued study therapy owing to
adverse events or physician decision. Two to fifteen percentage
experienced grade 3–5 non-haematological toxicities. The early
stopping rules for excessive toxicities were not met, thus the
planned accrual was completed. The most common non-hae-
matological toxicities and haematological toxicities are listed in
Table 2. The most common graded 3–4 non-haematological
toxicities included diarrhoea (15%), infection (15%), fatigue
(8%), dehydration (4%) and liver enzyme abnormalities (4%).
The most common grade 3–4 haematological toxicity included
neutropenia (23%), thrombocytopenia (6%) and anaemia
(4%).
Outcomes
At the time of analysis, 41 (85%) patients had already died. The
median, 1- and 2-year OS for the 29 patients with pancreatic
cancer was 17.6 months, 60.7% [95% confidence interval (CI):
0.450–0.818] and 32.1% (95% CI: 0.188–0.551), respectively.
Table 1 Pathological characteristics
Pancreatic cancer Other cancer
Overall stage
I 2 1
II 27 19
III 0 1
IV 0 0
T-stage 1
1 1 1
2 4 7
3 24 11
4 0 2
N-stage
0 8 2
1 21 15
X 0 4
Differentiation
Well 1 3
Moderate 8 9
Poor 20 8
NR 0 1
Lymphovascular involvement
Y 19 17
N 8 1
NR 2 3
CA 19-9
< 40 20 14
40–100 6 5
> 100 3 2
NR, not reported; Y, yes; N, No.
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The median, 1- and 2-year OS for the 21 patients with ampullary
and biliary cancers was 23.8 months, 75% (95% CI: 0.58–0.966)
and 49.1% (95% CI: 0.312–0.773), respectively (Fig. 1). Exclud-
ing all ampullary cancer patients, the 12 patients with biliary
tract malignancies had a median OS of 27.6 months (95%CI:
9.5–57.1).
Disease recurrence was noted in 40 of 48 patients (83%).
The majority of recurrence occurred in the liver (37.5%), peri-
toneum (20%) and lung (17.5%). The median recurrence-free
survivals for pancreatic cancer and ampullary/biliary cancers
were 9.6 and 12.7 months, respectively (Fig. 1). For the 12
patients with biliary tract cancers (excluding ampullary cancer),
the median PFS was 16.25 months (95% CI: 5.8 – 57.1).
For the 30 patients who completed all components of study
therapy, the median and 1-year OS for the 14 pancreatic can-
cer patients was 24.5 months and 78.6% (95% CI: 0.59–1).
The median DFS was 12.8 months. For the 16 patients with
biliary tract/ampullary cancers who completed all study treat-
ment, the median and 1 year OS was 23.8 months and 81.2%
(95% CI: 0.642–1), respectively. The median DFS was
15.0 months.
Discussion
This single-institution Phase II study demonstrated the feasibil-
ity of administering adjuvant 5FU-based chemoradiation with
pre- and post-RT gemcitabine with docetaxel. The current regi-
men was evaluated to build on the RTOG 9704 platform that
initially showed an improvement in 3-year OS with gemcita-
bine-based chemoradiation. An updated report on the results
of RTOG 9704 no longer demonstrated an overall survival
improvement at 5 years.12 The diminution of OS benefit asso-
ciated with the gemcitabine arm was attributed to subsequent
salvage therapies, disproportionately higher T3/T4 disease in
this arm and possibly the prolonged interruption of systemic
chemotherapy necessitated by chemoradiation. This last issue is
pertinent to the present study. Although two cycles of gemcita-
bine with docetaxel were administered prior to chemoradia-
tion, an average of 12–14 weeks occurred during the last
systemic therapy to the resumption of gemcitabine/docetaxel.
Moreover, systemic chemotherapy was administered for a
longer period (6 months) for both CONKO-001 and ESPAC-3
studies whereas systemic therapy in this study was interrupted
and only given for a total of four cycles (3 months). Lastly, the
benefit of radiation therapy in the adjuvant setting, and the
optimal timing of RT delivery, if given, has yet to be con-
firmed. In the present study, fluoropyrimidine-based radiation
was given, and RT was sandwiched between systemic therapy.
Current clinical practice utilized systemic chemotherapy alone
or chemotherapy plus consolidative chemoRT in the adjuvant
treatment of pancreatic cancer. The ongoing RTOG 0848 is
evaluating six cycles of adjuvant gemcitabine with or without
consolidative fluoropyrimidine-based chemoradiotherapy after
systemic therapy (Table 3).
The addition of a taxane to gemcitabine in the adjuvant set-
ting of pancreaticobiliary neoplasms is of interest especially in
light of the positive results of gemcitabine with nab-paclitaxel
in metastatic pancreatic cancer.19 Our study utilized docetaxel
with gemcitabine based on multiple Phase II data in pancreatic
Table 2 Toxicities
N = 48 Grade (1–2) (%) Grade (3–4) (%)
Mucositis 31 2
Nausea 48 4
Vomiting 23 4
Diarrhoea 31 15
Dehydration 17 4
Weight loss 27 0
Fatigue 67 8
Renal toxicity 13 0
Hepatotoxicity 69 4
Infection 13 15
Neutropenia 46 23
Anaemia 65 4
Thrombocytopenia 46 6
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Figure 1 Overall survival and disease-free survival of pancreatic
cancer patients and others (ampullary and biliary tract cancer)
patients who underwent the study
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and biliary cancers demonstrating activity against these malig-
nancies.17,20–24 In metastatic pancreatic cancer, gemcitabine
with docetaxel is associated with response rates of 12–20%17,20
although the ECOG study reported no superiority among sev-
eral regimens including gemcitabine/cisplatin or gemcitabine
alone.20 In the neoadjuvant setting for locally advanced pancre-
atic cancer, docetaxel with gemcitabine has been associated
with responses as high as 50% and increased resection
rates.21,22 To our knowledge, this is the only completed adju-
vant trial using the combination of docetaxel and gemcitabine
for pancreaticobiliary cancers.
Gemcitabine with docetaxel appears to be tolerable with
manageable toxicities when given in the adjuvant setting for
pancreaticobiliary cancers. Only 20% developed severe adverse
events. These toxicities were likely related more to chemoradia-
tion than to gemcitabine/docetaxel as the majority of toxicities
were gastrointestinal adverse events. For the 30 patients who
actually completed all aspects of the regimen, the median OS
for patients with pancreatic cancer of 24.5 months is compara-
ble with those reported by CONKO-1, RTOG 9704 and
ESPAC-3. The median OS for biliary tract cancers reaching
23.8 months is also encouraging. The APACT study currently
explores the use of nab-paclitaxel with gemcitabine as adjuvant
therapy for patients with resected pancreatic cancer.
There are several limitations of this study. This study is a
single institution Phase II trial. Thus clinical bias would be a
limitation. One significant issue was the presence of competing
studies that limited our enrolment. Compared with the inter-
feron-based study conducted at our institution during the
same period,25 patients enrolled in this study had a significant
delay in initiating adjuvant therapy from the time of surgery.
The median time from surgery date to chemotherapy was
61 days (range: 33–195). Twenty-seven (54%) patients started
therapy > 60 days after surgery. Seven (14%) had delayed
adjuvant therapy of >90 days post-resection. Fifteen (30%)
patients experienced significant post-operative morbidity
including infection (8 patients), cardiac (3 patients), gastroin-
testinal (3), gastrointestinal bleed (1) and metabolic (1). These
results are comparable to those experienced in our interferon-
based adjuvant therapy.25 This may in part explain our inferior
outcomes.
Another is the inclusion of multiple gastrointestinal malig-
nancies such as pancreatic cancer, ampullary cancer, gallblad-
der cancer and intra- and extrahepatic cholangiocarcinoma.
Clinical and genomic data demonstrates that these are hetero-
geneous entities with varying clinical behaviours and outcomes.
As feasibility and tolerability of gemcitabine and docetaxel-
based chemoradiation was the main endpoint for the study, we
Table 3 Summary of treatment, median overall survival (OS), disease-free survival (DFS) and 5-year OS in previous studies
Study No. Treatment Median PFS Median OS 5 year OS
GITSG 1985 43 Obs 9 11 months 8%
chemoRT 11 20 months 19%
CONKO 368 Obs 6.7 12%
Gemcitabine 13.4 23%
ESPAC-1 289 Obs No RF S reported 16.9 10.7%
5FU 21.6 29%
ESPAC -3
(Pancreatic)
1088 5FU 14.1 23.0 48.1%(24 months OS)
Gemcitabine 14.3 23.6 49.1%
RTOG 9704 538 5FU-RT NR 17.1 18%
Gem-RT 20.5 22%
ESPAC-3
(Periampullary)
434 Obs 19.5 35.2 NR
5FU 23 38.9
Gem 29.1 45.7
Gallbladder
(Takada et al.)
112 No adjuvant 11.9 16.4 14.4
Adj chemo 12.3 14.1 26
Cho
Completed therapy
Pancreatic 30 12.8 24.5 NR
Biliary 15.0 23.8
All patients
Pancreatic 48 9.6 17.6
Biliary 12.7 23.8
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included all these groups and described their outcomes. Also,
clinically and pathologically, tumours in the periampullary
region may be difficult to differentiate from true pancreatic
cancer or extrahepatic cholangiocarcinoma.
Currently, evidence for the use of adjuvant therapy for bili-
ary tract cancers is limited. The rarity of each subtype of bili-
ary tract cancers precluded the completion of large enough
randomized studies to establish standard treatment recommen-
dations. A meta-analysis did confirm a potential benefit for the
use of adjuvant therapy in node positive and margin positive
resected biliary tract cancers.16 Patients with gallbladder cancer
derived a survival benefit from adjuvant mitomycin C and 5FU
resulting in 5-year DFS and OS rates of 20.3% and 26%,
respectively, compared with 11.6% and 14.4%.15 All other sub-
groups, including pancreatic cancer, ampullary cancer and
other biliary tract cancer did not benefit from this regimen.
Only recently is there evidence for adjuvant therapy for
periampullary cancers. The ESPAC-3 periampullary study
randomized 428 patients (297 with ampullary, 96 with bile
duct cancer and 35 with other cancers) to 5FU or gemcitabine
or observation. The primary analysis did not confirm any
significant benefit associated with adjuvant chemotherapy for
periampullary cancer (a median survival of 43.1 months com-
pared with 35.2 months for observation, HR 0.86, P = 0.25).
After adjusting for prognostic variables using multiple regres-
sion analysis, there was a significant, albeit modest, benefit
favouring adjuvant chemotherapy compared with observation
for these tumours. The median survival for patients with 297
ampullary cancers in the different arms are as follows:
40.6 months in the observation arm; 57.8 months for the 5FU
arm and 70.8 months in the gemcitabine arm. The lower sur-
vival times were noted in spite of 5FU and gemcitabine treat-
ment for those with bile duct cancer (18.3 month for 5FU and
19.5 months for gemcitabine). The median survival for our
patients with biliary tract cancers, including periampullary and
gallbladder cancers is 23.8 months. The proportions of patients
in our study representing the different subgroups of biliary
tract cancers most probably influenced our results. When
ampullary cancer patients were excluded, the median DFS and
OS for the 12 biliary tract patients were better at 16.25 and
27.6 months, respectively. An extensive cooperative effort
would be warranted to assess the benefit of adjuvant therapy
for each subtype of biliary tract cancer.
Lastly, subsequent salvage therapy upon recurrence may
impact outcomes, including OS. Oxaliplatin-based therapy for
pancreaticobiliary cancers was only approved in the United
States at the latter portion of our study. Thus, of the 40
patients who experienced recurrence (eight of whom had early
recurrence during study therapy), nine patients never had any
salvage therapy, nine patients received only capecitabine single-
agent therapy, 12 did receive oxaliplatin-based therapy
(11 FOLFOX, 1 FOLFIRINOX), eight received further gemcita-
bine-based therapy and two received experimental therapies.
In summary, we have demonstrated the feasibility and
tolerability of a docetaxel/gemcitabine regimen pre- and post
5FU-RT in the adjuvant treatment of pancreaticobiliary can-
cers. Although feasible, the survival outcomes for pancreatic
cancer patients treated with this regimen and schedule appear
to be inferior to those reported with other regimens. Future
studies utilizing a different taxane (i.e. nab-paclitaxel) with
gemcitabine in the adjuvant treatment of both pancreatic can-
cer and biliary tumours may be appropriate given the signifi-
cant benefit of the gemcitabine/nab-paclitaxel regimen in
metastatic pancreatic cancer.
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